Connection
Ruofei Du to Treatment Outcome
This is a "connection" page, showing publications Ruofei Du has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.101 |
|
|
|
-
Du R, Wang X, Ma L, Larcher LM, Tang H, Zhou H, Chen C, Wang T. Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China. BMC Cancer. 2021 Feb 28; 21(1):206.
Score: 0.084
-
Patt YZ, Murad W, Fekrazad MH, Baron AD, Bansal P, Boumber Y, Steinberg K, Lee SJ, Bedrick E, Du R, Lee FC. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. Cancer Med. 2017 Sep; 6(9):2042-2051.
Score: 0.016